Anavex Life Sciences Corp (AVXL)

[Mikesc]

https://techbullion.com/is-early-alzheimers-treatable-new-clinical-trials-suggest-maybe/?fbclid=IwAR1_Nd0DS2JHok6QP4gIgzOuzljD6zAwJt221OhQ6d-Cq2bLkbcAO1knU7M

A New Approach to the Treatment of Early Alzheimer’s Shows Great Promise

ANAVEX2-73 (blarcamesine) is currently reaching the end of its clinical trials, but has shown to be highly effective in slowing down the progression of early Alzheimer’s, along with improving cognition. The medication helps brain cells resist the damage caused by Alzheimer’s and maintains neuroplasticity. Trial participants taking ANAVEX2-73 were 84% more likely to have improved mental function at the end of the treatment phase, and reported little-to-no adverse side effects.

“ANAVEX2-73 is different from other treatment options that currently exist for Alzheimer’s because science indicates that ANAVEX2-73 has a better side effect profile. For example, ANAVEX2-73 does not have any GI side effects. Additionally, ANAVEX2-73 has a longer duration of positive therapeutic impact than existing treatment options for Alzheimer’s diseases,” explains Prof. Dr. Timo Grimmer.